89bio Company Overview
About 89bio
89bio (NASDAQ:ETNB) is a biopharmaceutical company deeply engaged in the development and innovation of therapies targeting liver and cardio-metabolic diseases. With a robust focus on creating solutions for nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and other disorders, 89bio is dedicated to addressing unmet medical needs through a pipeline of potentially groundbreaking treatments. Their lead product candidate, pegozafermin, represents a significant part of their commitment to advancing healthcare and improving patient outcomes. The objective of 89bio is to pioneer effective and safer treatments that can greatly enhance the quality of life for individuals suffering from these chronic conditions, emphasizing their dedication to scientific excellence and patient well-being.
Snapshot
Operations
Products and/or services of 89bio
- PEGylated FGF21 analog for nonalcoholic steatohepatitis (NASH) aimed at reducing liver fat and improving liver health.
- Therapies for severe hypertriglyceridemia to lower triglyceride levels and reduce cardiovascular risk.
- Products targeting glycemic control for diabetes management, improving health outcomes for diabetic patients.
- Development of biologic treatments for obesity to aid in weight loss and improve metabolic health.
- Innovative pipelines for the treatment of cardiovascular diseases focusing on reducing major adverse cardiac events.
- Research into novel mechanisms for managing chronic kidney disease, focusing on slowing disease progression.
89bio executive team
- Mr. Rohan PalekarCEO & Director
- Mr. Ryan Stephen MartinsChief Financial Officer
- Mr. Francis W. Sarena J.D.Chief Operating Officer
- Mr. Quoc Le-NguyenChief Technical Officer
- Dr. Harry Mansbach M.D.Chief Medical Officer
- Mr. Shiva K. Natarajan CPASenior Vice President of Finance & Principal Accounting Officer
- Ms. Annie J. Chang M.B.A.VP of Investor Relations & Corporate Communications
- Ms. Amanda KuriharaVice President of People & Culture
- Ms. Melissa AbelSenior Vice President of Commercial Strategy
- Mr. Michael BaldwinSenior VP & Head of Quality